VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Drug Patent Profile

When do Vaprisol In 5% Dextrose In Plastic Container patents expire, and when can generic versions of Vaprisol In 5% Dextrose In Plastic Container launch?

Vaprisol In 5% Dextrose In Plastic Container is a drug marketed by Cumberland and is included in one NDA.

The generic ingredient in VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER is conivaptan hydrochloride. Additional details are available on the conivaptan hydrochloride profile page.

Summary for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	16
DailyMed Link:	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jesse Corry	Phase 1
University of Florida	Phase 2
Rigshospitalet, Denmark	Phase 4

See all VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008		RX	Yes	Yes

Expired US Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008

International Patents for VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

See the table below for patents covering VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69434032
Australia	683483
Spain	2198418
Hungary	T74582
New Zealand	268671	FUSED BENZAZEPIN-1-YL-CARBONYLPHENYL DERIVATIVES
Australia	7195794
Austria	239726

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VAPRISOL in 5% Dextrose

Introduction to VAPRISOL

VAPRISOL, or conivaptan hydrochloride injection, is a vasopressin antagonist used primarily to treat euvolemic hyponatremia, a condition characterized by low sodium levels in the blood without significant dehydration. Here, we delve into the market dynamics and financial trajectory of VAPRISOL, particularly in its formulation with 5% dextrose.

Market Drivers

The global vasopressin antagonists market, which includes VAPRISOL, is driven by several key factors:

Rise in Prevalence of Diabetes and Hypertension

The increasing prevalence of diabetes and hypertension is a significant driver for the vasopressin antagonists market. These conditions often lead to complications such as hyponatremia, for which VAPRISOL is prescribed[1].

Technological Advancements

Advancements in drug delivery systems, such as the premixed solution of VAPRISOL in 5% dextrose, enhance patient compliance and treatment efficacy. This technological progress is expected to propel market expansion[1].

Increased Awareness

Growing awareness among patients and healthcare professionals about the benefits of vasopressin antagonists, including VAPRISOL, is fueling market growth. This increased awareness leads to higher adoption rates and broader usage[1].

Market Restraints

Despite the positive drivers, there are several restraints that affect the market dynamics of VAPRISOL:

Stringent Regulatory Guidelines

The pharmaceutical industry is heavily regulated, and vasopressin antagonists are no exception. Stringent regulatory guidelines can slow down the approval process and limit market expansion[1].

High Cost

The high cost associated with these medications is a significant barrier to market growth. Patients and healthcare systems often face challenges in affording these treatments, which can limit the market's potential[1].

Financial Trajectory

The financial trajectory of VAPRISOL and the broader vasopressin antagonists market is promising but comes with its challenges.

Market Size and Growth Rate

The global vasopressin antagonists market is projected to reach more than $2.7 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.9% from 2023 to 2031. This growth indicates a strong financial trajectory for drugs like VAPRISOL[1].

Segmentation and Market Share

The tolvaptan segment, which is another type of vasopressin antagonist, held the largest share in 2022. However, VAPRISOL, particularly in its 5% dextrose formulation, remains a significant player in the market. North America is expected to account for a significant share during the forecast period, driven by high healthcare spending and advanced medical infrastructure[1].

Distribution and Administration

The distribution and administration of VAPRISOL in 5% dextrose are crucial aspects of its market dynamics:

Distribution Channels

VAPRISOL is distributed through various channels, including retail pharmacies, hospital pharmacies, and online pharmacies. The convenience and accessibility of these channels contribute to the drug's market performance[1].

Administration and Compatibility

VAPRISOL must be diluted only with 5% Dextrose Injection and is stable for up to 24 hours after mixing. It should not be mixed or administered with Lactated Ringer’s Injection or 0.9% Sodium Chloride Injection. This specificity in administration can affect its adoption and usage[3][4].

Clinical Efficacy and Patient Outcomes

The clinical efficacy of VAPRISOL is a key factor in its market success:

Efficacy in Hyponatremia Treatment

In clinical studies, VAPRISOL has shown significant efficacy in treating euvolemic hyponatremia. For example, following treatment with 40 mg/day of intravenous VAPRISOL, 79% of patients achieved an increase of ≥ 4 mEq/L in serum sodium concentration[4].

Patient Outcomes

The drug's ability to correct serum sodium levels effectively and safely enhances patient outcomes, which in turn boosts its market reputation and adoption[2].

Regional Market Analysis

The market for VAPRISOL varies by region:

North America

North America is expected to account for a significant share of the vasopressin antagonists market during the forecast period. This is due to the region's advanced healthcare infrastructure and high spending on pharmaceuticals[1].

Europe and Other Regions

Europe, Latin America, and the Middle East & Africa also represent significant markets for VAPRISOL. Each region has its unique market dynamics, influenced by local healthcare policies, patient demographics, and economic factors[1].

Key Takeaways

• Market Growth: The vasopressin antagonists market, including VAPRISOL, is expected to grow at a CAGR of 4.9% from 2023 to 2031.
• Drivers: Rise in prevalence of diabetes and hypertension, technological advancements, and increased awareness are key drivers.
• Restraints: Stringent regulatory guidelines and high costs are significant restraints.
• Clinical Efficacy: VAPRISOL has shown strong efficacy in treating euvolemic hyponatremia.
• Regional Markets: North America, Europe, Latin America, and the Middle East & Africa are key regions for market growth.

FAQs

Q: What is VAPRISOL used for? A: VAPRISOL is used to treat euvolemic hyponatremia, a condition characterized by low sodium levels in the blood without significant dehydration.

Q: How is VAPRISOL administered? A: VAPRISOL must be diluted only with 5% Dextrose Injection and is administered intravenously, either as a continuous infusion or a loading dose followed by a continuous infusion.

Q: What are the key drivers of the vasopressin antagonists market? A: The key drivers include the rise in prevalence of diabetes and hypertension, technological advancements in drug delivery systems, and increased awareness among patients and healthcare professionals.

Q: What are the restraints to the market growth of VAPRISOL? A: Stringent regulatory guidelines and the high cost associated with these medications are significant restraints.

Q: What is the projected market size of the vasopressin antagonists market by 2031? A: The global vasopressin antagonists market is projected to reach more than $2.7 billion by 2031.

Cited Sources

1. Transparency Market Research: Vasopressin Antagonists Market Size, Trends, Growth & Forecast.
2. FDA: Vaprisol (conivaptan hydrochloride injection) - accessdata.fda.gov.
3. FDA: NDA 21-697/S-001 - accessdata.fda.gov.
4. Drugs.com: Vaprisol: Package Insert / Prescribing Information.